Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-14
2006-02-14
McKelvey, Terry (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S375000, C514S012200, C530S300000, C530S324000, C530S350000
Reexamination Certificate
active
06998383
ABSTRACT:
The present invention provides a RANK (receptor activator of NF-κB) inhibitor consisted of a TRAF-6 (TNF receptor-associated factor-6) binding domain attached to a leader sequence. The peptide inhibitor inhibits RANKL (RANK ligand)-mediated osteoclast differentiation, thus indicating that targeted disruption of interaction between RANK and TRAF6 may prove useful as a therapeutic for metabolic bone disorders, leukemia, arthritis, and metastatic cancer of the bone.
REFERENCES:
patent: 5843678 (1998-12-01), Boyle
patent: 6017729 (2000-01-01), Anderson et al.
patent: 6271349 (2001-08-01), Dougall et al.
patent: WO 99/58674 (1999-11-01), None
Caldwell, Yakubutsu Dotai (Xenobiotic Metabolism and Disposition), 1996, vol. 11(1): pp. 119-125.
Yasuda, H. et al.: Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG); A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro,The Endocrine Society, 1998, vol. 139, No. 3.
Zhang, Y. Et al.: Tumor Necrosis Factor-a (TNF) Stimulates RANKL-induced Osteoclastogenesis via Coupling of TNF Type 1 Receptor and RANK Signaling Pathways,The Journal of Biological Chemistry, 2001, vol. 276, No. 1, pp. 563-568.
Takayanagi, H. et al.: T-cell-mediated regulation of Osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ,Nature, 2000, vol. 408.
Aggarwal Bharat
Darnay Bryant G.
Singh Sujay
Fulbright & Jaworski L.L.P.
McKelvey Terry
Research Development Corporation
LandOfFree
Inhibitors of receptor activator of NF-κB and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of receptor activator of NF-κB and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of receptor activator of NF-κB and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3666146